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The Role of Hyperuricemia in the Increased Cytokine Production After
Lipopolysaccharide Challenge in Neutropenic Mice
By Mihai G. Netea, Bart Jan Kullberg, Willem L. Blok, Romana T. Netea, and Jos W.M. Van der Meer
Patients with severe granulocytopenia are more susceptible 
to severe infections and sepsis. Proinflammatory cytokines 
such as tumor necrosis factor-a (TNF), interleukin-la (IL- 
1a), and IL-1/3 play an important role in the pathophysiology 
of sepsis. The profile of these proinflammatory cytokines 
after lipopolysccharide (LPS) challenge in cyclophospha­
mide-induced neutropenic mice was assessed, and possible 
mechanisms responsible for the modified cytokine produc­
tion were studied. After LPS, both circulating concentrations 
of TNF and IL-1 a in neutropenic mice were 50% to 200% 
higher than those of controls, whereas IL-1/Ì concentrations 
were not modified. The kinetics of cytokine production were 
similar in neutropenic and control animals. The susceptibil­
ity of neutropenic mice to an LPS challenge was increased. 
The observed overproduction of TNF and IL-1 a was not due
to a direct effect of cyclophosphamide treatment. Because 
circulating concentrations of uric acid were increased in the 
neutropenic mice, the effect of hypouricemic treatment with 
allopurinol and sodium bicarbonate was investigated; such 
treatment in neutropenic mice challenged with LPS was fol­
lowed by an improved survival and a reduced proinflamma­
tory cytokine production towards the concentrations 
in control mice. Hyperuricemia induced by repeated adminis­
trations of uric acid in normal mice led to an increased TIMF 
production after LPS. In conclusion, neutropenic mice re­
spond with enhanced cytokine production and increased 
susceptibility to an LPS challenge, and hyperuricemia proba­
bly plays an important role in this phenomenon.
© 1997 by The American Society of Hematology.
ATIENTS WITH granulocytopenia may develop severe 
and potentially lethal infections, with the relation be­
tween granulocytopenia and the incidence of infection being 
well documented.1 Interleukin-1 a  (IL-1 a ) f IL-1/3, and tumor 
necrosis factor-a (TNF) are proinflammatory cytokines that
MATERIALS AND METHODS
Animals. Female Swiss mice who were 6 to 8 weeks old and 
weighed 20 to 25 g were obtained from a local colony. The animals 
were fed standard laboratory chow (Hope Farms, Woerden, The 
Netherlands) and housed under specific pathogen-free conditions.
play a central role in the pa thophysio logy  o f  sepsis.2 Circu- The experiments were approved by the ethical committee on animal
lating concentrations of TNF and IL-1 can be found during 
sepsis, and clinical studies have shown a correlation between 
the concentration of these cytokines and the severity of dis­
ease and a poor outcome.3,4 Treatment with anti-TNF anti­
bodies protects against septic shock in experimental gram- 
negative bacteremia.3'6 The administration of either of the 
naturally occuring antagonists of IL-1 and TNF, ie, IL-1 
receptor antagonist and soluble TNF receptors, has been 
shown to be effective in lethal endotoxemia and in models 
of experimental infection.7'9 Despite their importance in sep­
sis and the higher incidence of severe infections in neutro­
penic hosts, little is known about the proinflammatory cyto­
kine profile during neutropenia.
In a recent report, increased TNFo; and IL-1/3 serum con­
centrations in neutropenic children with fever have been 
described.10 Patients with granulocytopenia reportedly had 
increased IL-6 serum levels preceding febrile episodes. 
Moreover, in animal models, cytokine concentrations during 
experimental Candida albicans infection were higher in neu­
tropenic mice when compared with control animals,12-" and 
TNF synthesis was increased in neutropenic animals after 
endotoxin challenge in vivo.14 These data indicate that neu­
tropenic hosts may produce more proinflammatory cytokines
,  h
an occurs.
The aim of the present study was to investigate the in­
creased cytokine production in mice rendered granulocyto­
penic by cyclophophamide and challenged with lipopolysac­
charide (LPS) and to show the possible mechanisms 
responsible for this phenomenon. We investigated whether 
the cyclophosphamide treatment could have directly influ­
enced the cytokine concentrations. Neutropenia induced by 
chemotherapy is often followed by hyperuricemia. Because 
it is known that urate crystals are able to stimulate the synthe­
sis of proinflammatory cytokines,15,16 we tested the hypothe­
sis that the increased uric acid concentrations are involved 
in the increased cytokine synthesis in neutropenic mice.
experiments of the Catholic University Nijmegen (Nijmegen, The 
Netherlands).
Treatment o f mice. Cyclophosphamide was obtained from Bris­
tol-Myers Squibb B.V. (Weesp, The Netherlands), allopurinol from 
Multipharma B.V. (Weesp, The Netherlands), and catalase from 
Sigma Chemical Co (St Louis, MO). Uric acid and sodium bicarbon­
ate were obtained from Boom B.V. (Meppel, The Netherlands). Neu­
tropenia was induced in the animals by two subcutaneous injections 
of cyclophosphamide of 150 mg/kg on day - 4  (before LPS chal­
lenge) and. 100 mg/kg on day - 1 .  As described before, in this model 
of neutropenia, the neutrophil counts are very low ( I OVmL).1 ' Also, 
the number of lymphocytes and monocytes are reduced, but not as 
strongly as the neutrophils. In some experiments, mice received 
allopurinol by gastric instillation (Gl) at two daily doses of 40 mg/ 
kg or sodium bicarbonate by GI at 100 mg/kg twice daily (BID), 
starting on day -4 .  Catalase (32,000 U/mouse) was administered 
intraperitoneally 1 hour before LPS challenge. Uric acid was admin­
istered by GI either as a single dose of 300 mg/kg 1 hour before 
LPS or as repeated administration of 300 mg/kg BID from day —4 
to day - 1 .  In all experiments, the control groups received 0.9% 
NaCl as placebo by the same route.
Endotoxemia model. LPS (Escherichia coli serotype 055: B5) was
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obtained from Sigma. Groups of normal and neutropenic mice were groups, detectable levels o f  T N F appeared in the circulation
30 minutes after LPS, with a peak at 90 minutes and ainjected intraperitoneally with LPS (10 /j.g/mouse). Ninety minutes 
and 4 hours after challenge with LPS, 5 animals from each group 
were anesthetized with ether and bled from the retroorbital plexus 
for measurement of circulating cytokine concentrations. Uric acid 
concentrations were also assessed. In a separate experiment, survival 
was assessed daily for 7 days in groups of 10 normal and neutropenic
mice injected with LPS at 1 mg/mouse. In additional experiments, 
normal and neutropenic mice were treated with sodium bicarbonate 
as described above and survival was assessed after LPS challenge.
Circulating cytokines. The kinetics of TNFœ production during 
endotoxemia were studied in normal and neutropenic mice chal­
lenged with LPS (10 /j,g/mouse). Subgroups of 5 mice were killed, 
and plasma concentrations of TNF were determined before and 30 
minutes, 90 minutes, 4 hours, and 8 hours after the LPS challenge.
In separate experiments, the direct influence of cyclophosphamide 
on the cytokine production was studied by injecting the animals with 
a single dose of cyclophosphamide (150 mg/kg) 1 hour before LPS 
(10 /¿.g/mouse). Also, the influence of allopurinol, catalase, sodium 
bicarbonate, and uric acid on cytokine production in groups of 5 
normal and neutropenic mice was studied by treating the mice with 
these drugs (as described in detail above) before the LPS challenge 
(10 ß g/mouse).
Ex vivo cytokine production. Resident peritoneal macrophages 
of normal and neutropenic mice were harvested by rinsing the perito­
neal cavity aseptically with cold phosphate-buffered saline con­
taining 0.38% (wt/vol) sodium citrate. After centrifugation for 10 
minutes at 1,800 cpm and 4°C, cells were resuspended in R P M I1640 
(Dutch modification; Flow Laboratories, Irvine, UK) containing 1 
mmol/L pyruvate, 2 mmoI/L L-glutamine, and 1.00 fig/mL  of genta­
micin. A total of 105 cells/well were cultured in 96-well microtiter 
plates (Costar Corp, Cambridge, MA) in culture medium (final vol­
ume, 200 /iL) at 37°C. After 2 hours, the supernatant and the nonad­
herent cells were discarded and 200 /iL medium with or without 
LPS at a final concentration of 1 /¿g/mL was added. The supernatants 
were collected after 24 hours of incubation at 37°C and stored at
- 7 0  C until assay.
Cytokine measurements. TNFa, IL-1 a , and IL-1/3 concentra­
tions were determined using specific radioimmunoassays developed 
in our laboratory, as described in detail earlier.1*
Statistical analysis. Differences in concentrations of cytokines 
were analyzed using the Mann-Whitney test and by ANOVA where 
appropriate. Survival data were analyzed using the Kaplan-Meyer 
log rank test. Differences were considered significant at P < .05. 
All experiments were performed at least twice and used at least 5 
mice/group/time point for the plasma cytokine concentrations and 
10 mice/group for survival experiments. Data are presented as means 
± standard deviation.
RESULTS
Cytokine production in neutropenic mice. Ninety min­
utes after challenge with 10 pg  LPS, TNFa plasma concen­
trations in neutropenic mice were significantly higher than 
those of control mice (P < .001 by ANOVA in 5 separate
decrease thereafter.
Ex vivo cytokine, production. To investigate whether the 
tissue macrophages of neutropenic mice are able to produce 
more cytokines after an LPS challenge than normal macro­
phages, peritoneal macrophages were collected, adjusted to 
10s cells/well, and stimulated with LPS (1 //g/mL) for 24 
hours at 37°C. Macrophages from neutropenic animals se­
creted significantly more TNFa than those of control animals 
(Fig 2). IL-1 a  production by macrophages of neutropenic 
mice was slighltly, although not significantly, higher. No 
difference in IL-1/3 production was observed between the 
two groups (Fig 2).
Effect o f cyclophosphamide on cytokine production. To 
exclude a direct effect of cyclophosphamide on cytokine 
production, mice were injected with cyclophosphamide (150 
mg/kg) 1 hour before the LPS challenge. Ninety minutes 
after LPS challenge, the plasma concentration of TNF in the 
cyclophosphamide-treated mice was significantly lower than 
in placebo-treated mice (0.57 ± 0.09 v 1.78 ± 0.47 ng/mL, 
P <  .05). No difference in IL-1 a  concentrations was detected 
(67 ±  44 v 82 ± 42 pg/mL, P > .05), whereas IL-1/3 concen­
trations were below the detection limit in both groups. These 
results indicate that the increased cytokine production in 
neutropenic mice is not due to a direct effect of cyclophos­
phamide.
Modulation o f uric acid concentrations. Normal mice 
and mice rendered neutropenic by cyclophosphamide were
pretreated with allopurinol, an inhibitor of xanthine-oxidase 
known to decrease uric acid concentration. LPS challenge 
and cytokine measurements were performed as described 
above, and uric acid concentrations were determined in all 
mice. Uric acid concentrations were approximately threefold 
higher in neutropenic mice (0.029 ± 0.020 mmol/L, P <
.02) than in controls (0.012 — -| — 0.004 mmol/L) and were
restored towards normal values by treatment with allopurinol
(0.016 0.005 mmol/L; Fig 3). Allopurinol treatment was
also able to significantly decrease the TNF concentrations 
in the neutropenic mice {P <  .04; Fig 4). In normal mice 
treated with allopurinol, only a slight decrease in TNF con­
centration was observed. However, allopurinol did not re­
duce the circulating IL-1 a  concentration (Fig 4).
Because allopurinol is able not only to decrease the uric 
acid concentration, but also has antioxidant activities by de­
creasing the reactive oxigen intermediates (ROI), we investi­
gated which of these two effects is involved in the allopuri- 
nol-induced modulation of cytokine synthesis. Therefore, 
subgroups of normal and neutropenic animals were pre­
treated with catalase or sodium bicarbonate. Catalase has
experiments with similar results). A representative experi- antioxidant activities by scavenging ROI, with no effect on
ment is shown in Fig I A. The IL-1 a: concentration was uric acid concentration. On the other hand, by alkalizing the
higher 4 hours after LPS (P < .05, Fig 1 A). IL-1/3 concentra- urine and thus increasing the solubility of uric acid in urine,
lions were below detection limit at 90 minutes after the LPS sodium bicarbonate was able to decrease the uric acid con-
challenge and did not differ between normal and neutropenic 
animals 4 hours after LPS (Fig 1A). The kinetics of the 
TNF in response upon LPS challenge was also studied. No
enees were found between the kinetics of TNF produc­
tion in normal and neutropenic mice (Fig IB). In both
centration in neutropenic animals. In this experiment, bicar­
bonate-treated animals had an uric acid concentration of
0.030 ± 0.008 mmol/L, versus 0.055 ± 0.011 mmol/L in 
the placebo group (P < .05). As shown in Table 1, catalase 
was able to decrease TNF concentration both in normal and
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Fig 1. (A) Cytokine plasma concentrations 90 
minutes and 4 hours after an LPS challenge (10 /xg/ 
mouse) in normal (□) and neutropenic (■) mice. (B) 
Kinetics of TNF production in normal and neutro­
penic mice challenged with 10 /mg LPS, Data repre­
sent the mean ± SD. * P < .05. hours
neutropenic animals, whereas sodium bicarbonate decreased 
TNF significantly only in neutropenic animals. However, 
catalase was not able to influence the elevated IL-1 a  concen­
tration in neutropenic mice and even increased IL-1 a  in 
normal animals. Sodium bicarbonate was able to restore the 
IL-1 a  concentration to normal in neutropenic mice, while 
having no effect in nonneutropenic animals (Table 1). These 
data suggest that the increased uric acid concentrations in 
neutropenic mice are responsible, at least in part, for the
enee the synthesis of TNF 90 minutes after LPS challenge
(1 .1 H- 0.4 ng/mL v 1.5 ± 0.5 ng/mL, P >  .05), repeated
administration of uric acid led to a significant increase in 
the TNF production (2.3 ± 0.9 ng/mL, P < .02), arguing 
for an influence of a sustained hyperuricemia on cytokine 
production when mice are challenged with LPS.
LPS-I 
central
ed lethality. Because both TNF and IL-1 are
k-
iators of lethal endotoxemia, the effect of the
increased cytokine response in neutropenic mice on leth
observed overproduction of proinflammatory cytokines after induced by LPS was studied. Normal and neutropenic mice
an LPS challenge.
Hyperuricemia in normal animals. Hyperuricemia was
were challenged intravenously with 1 mg of LPS, and mor­
tality was assessed daily for 7 days. The neutropenic mice
induced in normal animals by the administration of uric acid were more susceptible to endotoxemia when compared with 
(300 mg/kg BID) for 4 days. The uric acid concentration normal mice (Fig 5). Treatment of mice with bicarbonate
did not influence the outcome in control mice, whereas im­
proving survival was seen in neutropenic animals, ie, 100% 
in bicarbonate-treated neutropenic mice versus 72% in non­
increased in treated animals from 0.010 ± 0.004 mmol/L to 
0.018 ± 0.005 mmol/L (P <  .03). A subgroup of mice 
received a single dose of uric acid to discern whether the
potential effect of uric acid is rapid or long-lasting hyperuri- treated animals (P < .05; Fig 5). The data represent two
cemia is necessary for the activation of tissue macrophages. 
Whereas the single administration of uric acid did not influ-
pooled experiments with 10 
ar in both experiments.
iroup were
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Fig 2. Ex vivo cytokine production capacity of peritoneal macro­
phages collected from normal (□) and neutropenic {■) mice stimu­
lated with LPS (1 fig/mL) in vitro for 24 hours at 37°C. Data represent 
the mean ± SD. * P < .05.
DISCUSSION
i
In this study, we have shown that neutropenia leads to an 
increased cytokine production upon LPS challenge in mice. 
This enhanced production of cytokines is accompanied by 
an increased susceptibility of neutropenic mice to a lethal 
challenge with LPS. Neutropenic animals have higher 
plasma uric acid concentrations when compared with those 
of controls, and this hyperuricemia is responsible, at least in 
part, for the increased cytokine production.
Few studies have been performed to assess the production 
of cytokines during neutropenia. Two studies have reported 
increased cytokine production in neutropenic mice infected 
with C albicans.'2'1* Another recent study reported greater 
cytokine production after an LPS challenge in neutropenic 
mice.14 This finding is in agreement with our observation 
that neutropenic mice produce greater amounts of proin­
flammatory cytokines after stimulation with LPS. Despite 
the increased peak of cytokine concentration, we observed 
similar kinetics of cytokine synthesis in normal and neutro­
penic mice, data that are also sustained by the study of 
Steinshamn et al.14
When macrophages from normal and neutropenic mice 
were stimulated ex vivo with LPS, the macrophages from
neutropenic ; more s in response
to LPS. Xun et aliy observed circulating concentrations of 
cytokines in mice treated with daily injections of busulfan 
and cyclophosphamide, even without any stimulation of the 
animals. All of these data argue that the enhanced cytokine 
production in neutropenic animals is the result of an in­
creased cytokine production by tissue macrophages that may 
already be in a state of activation at the time of the LPS 
challenge.
Little is known about the mechanisms responsible for the 
increased cytokine production during neutropenia. The ob­
servation that one single dose of cyclophosphamide shortly
before the LPS challenge decreases the TNF concentration, 
while the IL-1 production is unmodified, indicates that cyclo­
phosphamide is not directly responsible for the increased 
cytokine production observed during neutropenia. This find­
ing is in agreement with the earlier observation that cyclo­
phosphamide reduces the capacity of murine peritoneal mac­
rophages to produce TNF and IL-1.2(l In addition, similarly 
increased cytokine concentrations were found in mice ren­
dered granulocytopenic after sublethal 7 -irradiation (data not 
shown). This led us to the hypothesis that a product of leuko­
cyte damage (eg, uric acid) may be responsible for the in­
creased cytokine production during neutropenia.
Uric acid concentrations were sig in neu­
tropenic mice when compared with controls. It has been 
shown that uric acid crystals are able to stimulate cytokine 
production,15,16 although no data have been reported on the 
ability of soluble uric acid to influence cytokine production. 
In the present study, hypouricemic agents led to a decrease 
of both the levels of uric acid and the cytokine concentration 
in the circulation of neutropenic mice. Allopurinol is also 
able to influence the TNF production by inhibiting ROI,21 
and this may explain the inhibition of TNFa production 
observed in normal mice treated with allopurinol. Therefore, 
the influence of ROI on TNF and IL-1 a  synthesis was as­
sessed. Catalase, which decreases ROI21 and has no effects 
on uric acid concentrations, decreased TNF concentrations, 
indicating that indeed part of the effect of allopurinol may 
be due to ROI inhibition. In contrast, catalase was not able 
to inhibit the production of IL-1 a. On the other hand, bicar­
bonate was able to inhibit both TNF and IL-1 a  production, 
by decreasing the concentration of uric acid without affecting 
ROI. The biologic significance of these observations is fur­
ther stressed by the bénéficiai effect of bicarbonate on sur­
vival of neutropenic animals challenged with LPS. These 
data argue that hyperuricemia plays an important role in the 
increased cytokine production during neutropenia in mice.
This hypothesis was further tested by inducing hyperuri­
cemia in nonneutropenic mice. An immediate increase in 
circulating uric acid concentration by a single administration 
of uric acid did not increase the cytokine production. How­
ever, when a sustained hyperuricemia was induced for 4
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Fig 3. Uric acid concentrations in normal and neutropenic mice 
and in neutropenic mice treated with allopurinol (40 mg BID for 4 
days). Data represent the mean ± SD. * P < .05.
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Fig 4. The influence of allopu- 
rinol treatment (40 mg/kg BID 
for 4 days) on cytokine produc­
tion 90 minutes after an LPS ad« 
ministration (10 fxg/mouse) in 
normal (□) and neutropenic (■) 
mice. Data represent the mean 
± SD. * P < .05.
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days, the TNF production after LPS was higher when com­
pared with that of the placebo group. This finding suggests 
that the increased uric acid concentrations may induce an 
activation of tissue macrophages, leading to increased pro­
duction of cytokines upon stimulation.
In contrast to humans, the final product of the purine 
metabolism in mice is not uric acid but allantoin, due to the 
presence of urate oxidase. For this reason, mice have much 
lower circulating concentrations of uric acid than do humans. 
It is to be expected that, in the present study, the increased 
concentrations of uric acid in the neutropenic mice and the 
mice that received oral uric acid were accompanied by a 
parallel increase in the concentration of allantoin. Thus, the 
possibility that the higher allantoin concentrations, rather 
than the hyperuricemia, are responsible for the increased 
cytokine production in these experiments cannot be ex­
cluded.
There are also other mechanisms that could have influenced 
the cytokine production. Steinshamn et al14 argued for a role 
of reduced release of soluble TNF receptor p75 in the enhanced
Table 1. Circulating TNF and IL-1 a Concentrations 90 Minutes After 
an LPS Challenge (10 /ttg/Mouse) in Normal and Neutropenic Mice 
Treated With Saline (Control Group), Catalase (32,000 U/Mouse, 1
hour Before LPS), or Sodium Bicarbonate (100 mg/kg
BID Starting on Day -4)
TNFa (ng/mL) IL-1 a  (pg/mL)
Nonneutropenic
Control 2.1 ± 0.7 78 ± 13
Catalase 0.6 ± 0.6* 242 ± 105*
Bicarbonate 1.4 ± 0 ,9 58 ± 30
Neutropenic
Control 3.5 ± 0.8 114 ± 48
Catalase 0.15 ± 0.1 + 150 ± 59
Bicarbonate 0.7 ± 0.4* 72 ± 19*
* P < .05 V control, 
t  P < .01 y control.
TNF activity after LPS during neutropenia. However, although 
this mechanism may occur in vivo, it does not explain our 
observation that the cytokine production capacity of macro­
phages from neutropenic animals is increased when stimulated 
with LPS in vitro. It has also been shown that TNF and IL-1 
can act as important hematopoietic regulatory cytokines,22 and 
it cannot be excluded that neutropenia leads to increased 
production of these cytokines through a direct feedback mecha­
nism. Neutropenia may also activate other hematopoietic regu­
latory cytokines such as granulocyte-macrophage colony-stim­
ulating factor,223 which may stimulate the production of
ammatory
In conclusion, several mechanisms, including hyperuri­
cemia, may lead to a higher production of proinflammatory 
cytokines during neutropenia. The results of our study and 
the other experimental studies, together with the observed 
increased production of proinflammatory cytokines in neu­
tropenic patients,"1,11 suggest that this overproduction of cy-
100
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Fig 5. Survival of normal and neutropenic mice treated with saline 
or bicarbonate (100 mg/kg BID starting on day -4) after LPS chal­
lenge (1 mg/mouse). The data represent the pooled results of two 
experiments with at least 10 animals/group.
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